1. Home
  2. HEQ vs ZNTL Comparison

HEQ vs ZNTL Comparison

Compare HEQ & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEQ
  • ZNTL
  • Stock Information
  • Founded
  • HEQ 2011
  • ZNTL 2014
  • Country
  • HEQ United States
  • ZNTL United States
  • Employees
  • HEQ N/A
  • ZNTL N/A
  • Industry
  • HEQ Investment Managers
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • HEQ Finance
  • ZNTL Health Care
  • Exchange
  • HEQ Nasdaq
  • ZNTL Nasdaq
  • Market Cap
  • HEQ 126.9M
  • ZNTL 134.7M
  • IPO Year
  • HEQ N/A
  • ZNTL 2020
  • Fundamental
  • Price
  • HEQ $10.59
  • ZNTL $2.32
  • Analyst Decision
  • HEQ
  • ZNTL Buy
  • Analyst Count
  • HEQ 0
  • ZNTL 8
  • Target Price
  • HEQ N/A
  • ZNTL $8.53
  • AVG Volume (30 Days)
  • HEQ 43.1K
  • ZNTL 2.6M
  • Earning Date
  • HEQ 01-01-0001
  • ZNTL 03-04-2025
  • Dividend Yield
  • HEQ 9.78%
  • ZNTL N/A
  • EPS Growth
  • HEQ N/A
  • ZNTL N/A
  • EPS
  • HEQ N/A
  • ZNTL N/A
  • Revenue
  • HEQ N/A
  • ZNTL $40,560,000.00
  • Revenue This Year
  • HEQ N/A
  • ZNTL N/A
  • Revenue Next Year
  • HEQ N/A
  • ZNTL N/A
  • P/E Ratio
  • HEQ N/A
  • ZNTL N/A
  • Revenue Growth
  • HEQ N/A
  • ZNTL N/A
  • 52 Week Low
  • HEQ $9.08
  • ZNTL $1.61
  • 52 Week High
  • HEQ $11.84
  • ZNTL $18.07
  • Technical
  • Relative Strength Index (RSI)
  • HEQ 54.76
  • ZNTL 49.24
  • Support Level
  • HEQ $10.56
  • ZNTL $2.37
  • Resistance Level
  • HEQ $10.70
  • ZNTL $2.36
  • Average True Range (ATR)
  • HEQ 0.11
  • ZNTL 0.25
  • MACD
  • HEQ 0.01
  • ZNTL 0.08
  • Stochastic Oscillator
  • HEQ 75.00
  • ZNTL 69.27

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Share on Social Networks: